IN2012DN04940A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN04940A IN2012DN04940A IN4940DEN2012A IN2012DN04940A IN 2012DN04940 A IN2012DN04940 A IN 2012DN04940A IN 4940DEN2012 A IN4940DEN2012 A IN 4940DEN2012A IN 2012DN04940 A IN2012DN04940 A IN 2012DN04940A
- Authority
- IN
- India
- Prior art keywords
- disclosed
- hif
- immune response
- inducible factor
- hypoxia inducible
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 abstract 2
- 102000002177 Hypoxia-inducible factor-1 alpha Human genes 0.000 abstract 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010057249 Phagocytosis Diseases 0.000 abstract 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 abstract 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 210000001539 phagocyte Anatomy 0.000 abstract 1
- 230000008782 phagocytosis Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25891409P | 2009-11-06 | 2009-11-06 | |
US25891809P | 2009-11-06 | 2009-11-06 | |
PCT/US2010/055694 WO2011057115A1 (en) | 2009-11-06 | 2010-11-05 | Prolyl hydroxylase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN04940A true IN2012DN04940A (zh) | 2015-09-25 |
Family
ID=43970365
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4940DEN2012 IN2012DN04940A (zh) | 2009-11-06 | 2010-11-05 | |
IN4949DEN2012 IN2012DN04949A (zh) | 2009-11-06 | 2010-11-05 | |
IN4950DEN2012 IN2012DN04950A (zh) | 2009-11-06 | 2010-11-05 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4949DEN2012 IN2012DN04949A (zh) | 2009-11-06 | 2010-11-05 | |
IN4950DEN2012 IN2012DN04950A (zh) | 2009-11-06 | 2010-11-05 |
Country Status (27)
Country | Link |
---|---|
US (11) | US8778412B2 (zh) |
EP (9) | EP2496236B1 (zh) |
JP (6) | JP5591939B2 (zh) |
KR (8) | KR20140095105A (zh) |
CN (3) | CN102595896B (zh) |
AU (3) | AU2010314976B2 (zh) |
BR (3) | BR112012010762B1 (zh) |
CA (3) | CA2774039A1 (zh) |
DK (4) | DK2496084T3 (zh) |
ES (5) | ES2782999T3 (zh) |
HK (4) | HK1169275A1 (zh) |
HR (3) | HRP20130691T1 (zh) |
HU (1) | HUE026109T2 (zh) |
IL (4) | IL219611A (zh) |
IN (3) | IN2012DN04940A (zh) |
MX (4) | MX2012005275A (zh) |
MY (3) | MY161880A (zh) |
NO (1) | NO2853265T3 (zh) |
NZ (4) | NZ600396A (zh) |
PL (4) | PL2496236T4 (zh) |
PT (4) | PT2853265T (zh) |
RS (3) | RS54124B1 (zh) |
RU (3) | RU2518071C2 (zh) |
SI (2) | SI2649998T1 (zh) |
SM (1) | SMT201300096B (zh) |
WO (3) | WO2011057115A1 (zh) |
ZA (1) | ZA201204104B (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
MX2011007420A (es) | 2009-07-06 | 2011-12-14 | Akebia Therapeutics Inc | Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas. |
WO2011044492A1 (en) * | 2009-10-09 | 2011-04-14 | University Of Rochester | Methods of treatment and screening assays for hif-1alpha regulation |
CN102595896B (zh) | 2009-11-06 | 2016-02-17 | 爱尔皮奥治疗有限公司 | 提高低氧诱导因子-1α的稳定性的方法 |
NO2686520T3 (zh) | 2011-06-06 | 2018-03-17 | ||
WO2012170439A1 (en) * | 2011-06-06 | 2012-12-13 | The Ohio State University | Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
CA2911376C (en) * | 2013-03-15 | 2021-03-30 | University Of Southern California | Phenyl(sulfonylcarbamate) derivatives and pharmaceutical compositions thereof for the treatment of angiotensin-related diseases |
MX371382B (es) | 2013-03-15 | 2020-01-28 | Aerpio Therapeutics Inc | Composiciones, formulaciones y metodos para tratar enfermedades oculares. |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
CN114404414A (zh) | 2013-06-13 | 2022-04-29 | 阿克比治疗有限公司 | 用于治疗贫血症的组合物和方法 |
CN106232120B (zh) * | 2014-02-19 | 2021-01-08 | 爱尔皮奥治疗有限公司 | 制备n-苄基-3-羟基-4-取代的-吡啶-2-(1h)-酮的方法 |
JP6483148B2 (ja) | 2014-03-14 | 2019-03-13 | エアーピオ セラピューティクス インコーポレイテッド | HPTP−β阻害剤 |
US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
WO2016118858A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
BR112017021097B1 (pt) | 2015-04-01 | 2024-01-02 | Akebia Therapeutics, Inc | Formulação de dosagem oral e seu uso |
US10953036B2 (en) | 2017-11-20 | 2021-03-23 | University Of Georgia Research Foundation, Inc. | Compositions and methods of modulating HIF-2A to improve muscle generation and repair |
TWI822776B (zh) | 2018-05-09 | 2023-11-21 | 美商阿克比治療有限公司 | 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法 |
CN113164597A (zh) | 2018-09-24 | 2021-07-23 | 爱尔皮奥制药公司 | 靶向HPTP-β(VE-PTP)和VEGF的多特异性抗体 |
CN114980898A (zh) * | 2019-11-20 | 2022-08-30 | 安吉昂生物医药公司 | 用于治疗炎性肠病的方法 |
WO2021119033A1 (en) | 2019-12-09 | 2021-06-17 | Gb004, Inc. | Compositions and methods of treatment |
WO2021182490A1 (ja) * | 2020-03-11 | 2021-09-16 | キッセイ薬品工業株式会社 | イミダゾピリジノン化合物又はその塩の結晶 |
WO2022036269A1 (en) * | 2020-08-13 | 2022-02-17 | Gb004, Inc. | CRYSTALLINE FORMS OF AN HIF-1α PROLYL HYDROXYLASE INHIBITOR |
WO2022036267A1 (en) | 2020-08-13 | 2022-02-17 | Gb004, Inc. | Compositions and methods of treatment |
AU2022216810A1 (en) * | 2021-02-02 | 2023-08-24 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
KR102507532B1 (ko) * | 2022-09-14 | 2023-03-10 | 주식회사 에이치디에스바이오 | 락토바실러스 플란타룸 hac03 균주 및 플라보노이드를 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
CN116196314B (zh) * | 2023-05-04 | 2023-08-15 | 广州市妇女儿童医疗中心 | Ri-1或其盐在制备防治胃肠道疾病的药物中的应用 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
US3853900A (en) * | 1973-09-14 | 1974-12-10 | Searle & Co | 4-benzyloxy-2 (1h)-pyridones |
US5358949A (en) | 1986-03-05 | 1994-10-25 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives |
TW219933B (zh) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
DE4221583A1 (de) * | 1991-11-12 | 1993-05-13 | Bayer Ag | Substituierte biphenylpyridone |
DE4316077A1 (de) * | 1993-05-13 | 1994-11-17 | Bayer Ag | Substituierte Mono- und Bihydridylmethylpyridone |
ES2101420T3 (es) * | 1993-11-02 | 1997-07-01 | Hoechst Ag | Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. |
NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
US5789426A (en) * | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
US6046219A (en) * | 1995-01-20 | 2000-04-04 | Cornell Research Foundation, Inc. | Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation |
US5849587A (en) * | 1995-06-09 | 1998-12-15 | Cornell Research Foundation, Inc. | Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells |
AU5762896A (en) | 1996-04-30 | 1997-11-19 | Hoechst Aktiengesellschaft | 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and the ir use as drugs |
DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
UA66370C2 (en) * | 1997-12-16 | 2004-05-17 | Lilly Co Eli | Arylpiperazines having activity to setotonin 1 receptors |
US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
US6977266B2 (en) | 2000-12-28 | 2005-12-20 | Shionogi & Co., Ltd. | Pyridone derivatives having affinity for cannabinoid 2-type receptor |
US6855510B2 (en) * | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
WO2002074981A2 (en) * | 2001-03-21 | 2002-09-26 | Isis Innovation Ltd. | Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
US20030176317A1 (en) * | 2001-12-06 | 2003-09-18 | Volkmar Guenzler-Pukall | Stabilization of hypoxia inducible factor (HIF) alpha |
ATE308886T1 (de) | 2002-01-11 | 2005-11-15 | Rhodianyl | Verwendung von zinksulfid als akarizide |
US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
EP2156830A1 (en) | 2002-10-16 | 2010-02-24 | Isis Innovation Limited | Modulators of asparaginyl hydoxylase activity of FIH |
US6930117B2 (en) * | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
US6946479B2 (en) | 2002-11-09 | 2005-09-20 | The Procter & Gamble Company | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones |
WO2004080966A1 (ja) * | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
PL1644336T3 (pl) * | 2003-06-06 | 2011-07-29 | Fibrogen Inc | Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny |
US20060251638A1 (en) | 2003-06-06 | 2006-11-09 | Volkmar Guenzler-Pukall | Cytoprotection through the use of hif hydroxylase inhibitors |
US20050180952A1 (en) | 2003-08-26 | 2005-08-18 | Pettis Ronald J. | Methods for intradermal delivery of therapeutics agents |
WO2005041658A1 (ja) * | 2003-10-31 | 2005-05-12 | Earth Chemical Co., Ltd. | ゲル材 |
WO2005051933A1 (en) * | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby |
AU2005211349A1 (en) | 2004-01-30 | 2005-08-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors |
US20050258126A1 (en) | 2004-05-21 | 2005-11-24 | Aniceto Canamasas Puigbo | Double bottomed jar |
AU2005250412B2 (en) | 2004-05-28 | 2009-09-17 | Fibrogen, Inc. | HIF prolyl hydroxylase activity assay |
US7718624B2 (en) | 2004-09-01 | 2010-05-18 | Sitkovsky Michail V | Modulation of immune response and inflammation by targeting hypoxia inducible factors |
US20080213404A1 (en) | 2005-02-04 | 2008-09-04 | Johnson Randall S | Hif Modulating Compounds and Methods of Use Thereof |
US7588824B2 (en) * | 2005-02-25 | 2009-09-15 | The Regents Of The University Of California | Hydrogen cyano fullerene containing proton conducting membranes |
CA2603926A1 (en) * | 2005-04-08 | 2006-10-12 | Neuromed Pharmaceuticals Ltd. | Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain |
US8177417B2 (en) * | 2005-04-25 | 2012-05-15 | Harsco Technologies Corporation | Apparatus for continuous blending |
DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
JP5390184B2 (ja) * | 2005-06-06 | 2014-01-15 | ファイブローゲン、インコーポレーテッド | 貧血の改良された治療方法 |
US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
US20090176726A1 (en) | 2005-10-11 | 2009-07-09 | Fisher David E | Methods for treating mitf-related disorders |
US7728130B2 (en) | 2005-12-09 | 2010-06-01 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity |
WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
WO2007123777A2 (en) | 2006-03-30 | 2007-11-01 | Duke University | Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses |
RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
JP2009537558A (ja) | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
PE20080209A1 (es) | 2006-06-23 | 2008-05-15 | Smithkline Beecham Corp | Derivados de glicina como inhibidores de prolil hidroxilasa |
EP3026044B8 (en) * | 2006-06-26 | 2018-12-19 | Akebia Therapeutics, Inc. | Prolyl hydroxylase inhibitors and methods of use |
US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
JP5265381B2 (ja) | 2006-12-07 | 2013-08-14 | テルモ株式会社 | 輸液チューブセット |
WO2008076427A2 (en) * | 2006-12-18 | 2008-06-26 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
US7569726B2 (en) | 2007-04-18 | 2009-08-04 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
US20100056563A1 (en) | 2007-04-18 | 2010-03-04 | Deodialsingh Guiadeen | Novel 1.8-naphthyridine compounds |
EP2150251B9 (en) | 2007-05-04 | 2013-02-27 | Amgen, Inc | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
JP5349462B2 (ja) | 2007-05-16 | 2013-11-20 | メルク・シャープ・アンド・ドーム・コーポレーション | スピロインダロン |
TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
CA2696725A1 (en) | 2007-08-10 | 2009-03-26 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
FR2924205B1 (fr) | 2007-11-23 | 2013-08-16 | Air Liquide | Dispositif et procede de refrigeration cryogenique |
WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
AU2008329746A1 (en) | 2007-11-30 | 2009-06-04 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
AU2008331480A1 (en) | 2007-11-30 | 2009-06-11 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
EP2227475B1 (en) | 2007-12-03 | 2014-02-19 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
CN102119218A (zh) | 2007-12-13 | 2011-07-06 | 阿彻-丹尼尔斯-米德兰德公司 | 耐热酵母多形汉逊酵母在高温的产乙醇的木糖发酵 |
WO2009086044A1 (en) | 2007-12-19 | 2009-07-09 | Smith Kline Beecham Corporation | Prolyl hydroxylase inhibitors |
WO2009086592A1 (en) | 2008-01-04 | 2009-07-16 | Garvan Institute Of Medical Research | Method of increasing metabolism |
WO2009089547A1 (en) | 2008-01-11 | 2009-07-16 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
TR201809280T4 (tr) | 2009-01-12 | 2018-07-23 | Aerpio Therapeutics Inc | Vasküler sızıntı sendromunun tedavi edilmesine yönelik yöntemler. |
US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
MX2011007420A (es) | 2009-07-06 | 2011-12-14 | Akebia Therapeutics Inc | Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas. |
CN102595896B (zh) | 2009-11-06 | 2016-02-17 | 爱尔皮奥治疗有限公司 | 提高低氧诱导因子-1α的稳定性的方法 |
MX361520B (es) | 2010-10-07 | 2018-12-06 | Aerpio Therapeutics Inc | Composiciones y métodos para tratar edema ocular, neovascularización y enfermedades relacionadas. |
WO2012170439A1 (en) | 2011-06-06 | 2012-12-13 | The Ohio State University | Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
AU2012323849B2 (en) | 2011-10-13 | 2017-04-20 | EyePoint Pharmaceuticals, Inc. | Treatment of ocular disease |
CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
MX371382B (es) | 2013-03-15 | 2020-01-28 | Aerpio Therapeutics Inc | Composiciones, formulaciones y metodos para tratar enfermedades oculares. |
CN106232120B (zh) | 2014-02-19 | 2021-01-08 | 爱尔皮奥治疗有限公司 | 制备n-苄基-3-羟基-4-取代的-吡啶-2-(1h)-酮的方法 |
US9839423B2 (en) | 2014-02-24 | 2017-12-12 | Ethicon Llc | Implantable layers and methods for modifying the shape of the implantable layers for use with a surgical fastening instrument |
-
2010
- 2010-11-05 CN CN201080050210.1A patent/CN102595896B/zh not_active Expired - Fee Related
- 2010-11-05 IN IN4940DEN2012 patent/IN2012DN04940A/en unknown
- 2010-11-05 BR BR112012010762-3A patent/BR112012010762B1/pt not_active IP Right Cessation
- 2010-11-05 KR KR1020147017414A patent/KR20140095105A/ko active IP Right Grant
- 2010-11-05 ES ES15164257T patent/ES2782999T3/es active Active
- 2010-11-05 DK DK10829180.8T patent/DK2496084T3/en active
- 2010-11-05 KR KR1020157026346A patent/KR101591701B1/ko active IP Right Grant
- 2010-11-05 SI SI201030927T patent/SI2649998T1/sl unknown
- 2010-11-05 SI SI201030987T patent/SI2496084T1/sl unknown
- 2010-11-05 KR KR1020147008577A patent/KR20140048341A/ko active Application Filing
- 2010-11-05 IN IN4949DEN2012 patent/IN2012DN04949A/en unknown
- 2010-11-05 NZ NZ600396A patent/NZ600396A/en not_active IP Right Cessation
- 2010-11-05 BR BR112012010759-3A patent/BR112012010759B1/pt not_active IP Right Cessation
- 2010-11-05 RU RU2012123387/04A patent/RU2518071C2/ru not_active IP Right Cessation
- 2010-11-05 ES ES14193060.2T patent/ES2644998T3/es active Active
- 2010-11-05 MX MX2012005275A patent/MX2012005275A/es active IP Right Grant
- 2010-11-05 KR KR1020127014454A patent/KR101483831B1/ko active IP Right Grant
- 2010-11-05 WO PCT/US2010/055694 patent/WO2011057115A1/en active Application Filing
- 2010-11-05 MY MYPI2012001219A patent/MY161880A/en unknown
- 2010-11-05 ES ES10829180.8T patent/ES2541613T3/es active Active
- 2010-11-05 RS RS20150485A patent/RS54124B1/en unknown
- 2010-11-05 BR BR112012010766A patent/BR112012010766A2/pt not_active Application Discontinuation
- 2010-11-05 MY MYPI2012001216A patent/MY160066A/en unknown
- 2010-11-05 NZ NZ600400A patent/NZ600400A/en not_active IP Right Cessation
- 2010-11-05 NO NO14193060A patent/NO2853265T3/no unknown
- 2010-11-05 RS RS20130321A patent/RS52870B/en unknown
- 2010-11-05 PL PL10829176T patent/PL2496236T4/pl unknown
- 2010-11-05 US US12/940,883 patent/US8778412B2/en active Active
- 2010-11-05 JP JP2012537240A patent/JP5591939B2/ja not_active Expired - Fee Related
- 2010-11-05 MY MYPI2012001217A patent/MY163511A/en unknown
- 2010-11-05 PT PT141930602T patent/PT2853265T/pt unknown
- 2010-11-05 EP EP10829176.6A patent/EP2496236B1/en active Active
- 2010-11-05 PL PL14193060T patent/PL2853265T3/pl unknown
- 2010-11-05 CA CA2774039A patent/CA2774039A1/en not_active Abandoned
- 2010-11-05 EP EP10829180.8A patent/EP2496084B1/en active Active
- 2010-11-05 PT PT108291766T patent/PT2496236E/pt unknown
- 2010-11-05 KR KR1020127014522A patent/KR20120088833A/ko active Application Filing
- 2010-11-05 ES ES13165749.6T patent/ES2533128T3/es active Active
- 2010-11-05 CA CA2774043A patent/CA2774043C/en not_active Expired - Fee Related
- 2010-11-05 DK DK10829176.6T patent/DK2496236T3/da active
- 2010-11-05 EP EP14193060.2A patent/EP2853265B1/en not_active Not-in-force
- 2010-11-05 EP EP15154363.4A patent/EP2952192B1/en not_active Not-in-force
- 2010-11-05 US US12/940,891 patent/US8536181B2/en active Active
- 2010-11-05 EP EP10829174.1A patent/EP2496082B1/en not_active Not-in-force
- 2010-11-05 RU RU2012123386/15A patent/RU2521251C2/ru not_active IP Right Cessation
- 2010-11-05 JP JP2012537237A patent/JP5599467B2/ja not_active Expired - Fee Related
- 2010-11-05 RU RU2012123388/15A patent/RU2518416C2/ru not_active IP Right Cessation
- 2010-11-05 HU HUE10829180A patent/HUE026109T2/en unknown
- 2010-11-05 EP EP20150482.6A patent/EP3698794A1/en not_active Withdrawn
- 2010-11-05 PL PL13165749T patent/PL2649998T3/pl unknown
- 2010-11-05 MX MX2012005273A patent/MX2012005273A/es not_active Application Discontinuation
- 2010-11-05 PT PT131657496T patent/PT2649998E/pt unknown
- 2010-11-05 KR KR1020147026829A patent/KR20140122283A/ko not_active Application Discontinuation
- 2010-11-05 AU AU2010314976A patent/AU2010314976B2/en not_active Ceased
- 2010-11-05 WO PCT/US2010/055704 patent/WO2011057121A1/en active Application Filing
- 2010-11-05 AU AU2010314973A patent/AU2010314973B9/en not_active Ceased
- 2010-11-05 CA CA2774046A patent/CA2774046C/en not_active Expired - Fee Related
- 2010-11-05 AU AU2010314982A patent/AU2010314982B2/en not_active Ceased
- 2010-11-05 JP JP2012537236A patent/JP5627040B2/ja not_active Expired - Fee Related
- 2010-11-05 ES ES10829176T patent/ES2424122T3/es active Active
- 2010-11-05 US US12/940,901 patent/US8309537B2/en active Active
- 2010-11-05 IN IN4950DEN2012 patent/IN2012DN04950A/en unknown
- 2010-11-05 CN CN201080050181.9A patent/CN102612367B/zh not_active Expired - Fee Related
- 2010-11-05 EP EP13165749.6A patent/EP2649998B1/en not_active Not-in-force
- 2010-11-05 NZ NZ629733A patent/NZ629733A/en not_active IP Right Cessation
- 2010-11-05 PL PL10829180T patent/PL2496084T3/pl unknown
- 2010-11-05 WO PCT/US2010/055691 patent/WO2011057112A1/en active Application Filing
- 2010-11-05 DK DK13165749.6T patent/DK2649998T3/en active
- 2010-11-05 NZ NZ600405A patent/NZ600405A/en not_active IP Right Cessation
- 2010-11-05 KR KR1020157001507A patent/KR101613103B1/ko active IP Right Grant
- 2010-11-05 MX MX2013009454A patent/MX365138B/es unknown
- 2010-11-05 PT PT108291808T patent/PT2496084E/pt unknown
- 2010-11-05 KR KR1020127014419A patent/KR101445946B1/ko active IP Right Grant
- 2010-11-05 EP EP15164257.6A patent/EP2954899B1/en active Active
- 2010-11-05 DK DK14193060.2T patent/DK2853265T3/da active
- 2010-11-05 EP EP19174520.7A patent/EP3603644A1/en not_active Withdrawn
- 2010-11-05 RS RS20150173A patent/RS54010B1/en unknown
- 2010-11-05 MX MX2012005274A patent/MX2012005274A/es active IP Right Grant
- 2010-11-05 CN CN201080050212.0A patent/CN102638983B/zh not_active Expired - Fee Related
-
2012
- 2012-05-06 IL IL219611A patent/IL219611A/en not_active IP Right Cessation
- 2012-05-06 IL IL219610A patent/IL219610A/en active IP Right Grant
- 2012-05-06 IL IL219612A patent/IL219612A/en active IP Right Grant
- 2012-06-05 ZA ZA2012/04104A patent/ZA201204104B/en unknown
- 2012-10-11 HK HK12110021.8A patent/HK1169275A1/zh not_active IP Right Cessation
- 2012-10-11 HK HK12110020.9A patent/HK1169313A1/xx not_active IP Right Cessation
-
2013
- 2013-02-15 US US13/768,308 patent/US9045495B2/en not_active Expired - Fee Related
- 2013-02-19 US US13/770,135 patent/US8883774B2/en active Active
- 2013-07-23 HR HRP20130691AT patent/HRP20130691T1/hr unknown
- 2013-09-05 SM SM201300096T patent/SMT201300096B/xx unknown
-
2014
- 2014-03-07 JP JP2014045734A patent/JP2014139206A/ja not_active Withdrawn
- 2014-03-07 JP JP2014045733A patent/JP5865411B2/ja not_active Expired - Fee Related
- 2014-04-16 HK HK14103621.5A patent/HK1190334A1/zh not_active IP Right Cessation
- 2014-07-30 JP JP2014155145A patent/JP5961665B2/ja not_active Expired - Fee Related
- 2014-08-21 US US14/465,027 patent/US8999971B2/en not_active Expired - Fee Related
-
2015
- 2015-02-22 US US14/628,261 patent/US9278930B2/en not_active Expired - Fee Related
- 2015-04-16 US US14/688,216 patent/US9540326B2/en active Active
- 2015-05-04 HR HRP20150473TT patent/HRP20150473T1/hr unknown
- 2015-07-13 IL IL239918A patent/IL239918A0/en unknown
- 2015-07-14 HR HRP20150772TT patent/HRP20150772T1/hr unknown
- 2015-09-29 HK HK15109530.1A patent/HK1208806A1/zh unknown
-
2016
- 2016-12-01 US US15/366,437 patent/US20170298019A1/en not_active Abandoned
-
2018
- 2018-02-20 US US15/900,447 patent/US10562854B2/en not_active Expired - Fee Related
-
2021
- 2021-12-16 US US17/553,578 patent/US20220185778A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN04940A (zh) | ||
MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
MY164731A (en) | Compound | |
MX2012000709A (es) | Inhibidores de pirrolopiridina de cinasas. | |
PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
MY150697A (en) | Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha | |
EA201391720A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
UA83875C2 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
IN2012DN02081A (zh) | ||
MX2013012979A (es) | Piridina y derivados de pirazina. | |
MX351975B (es) | Composiciones y metodos para el tratamiento de infecciones y tumores. | |
IN2014DN08886A (zh) | ||
MX344335B (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
EA201390085A1 (ru) | Композиции ингибиторов киназ для лечения рака | |
MX2013004298A (es) | Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa. | |
MX2009013341A (es) | Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina. | |
TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
MX2013004004A (es) | Pirrolidinonas como inhibidores de metionina aminopeptidasa (metap-2). | |
MX2010003365A (es) | Derivados de tiazol para el tratamiento de cancer. | |
MX2011011083A (es) | Compuestos heterociclicos como inhibidores de mek. | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
MX342947B (es) | Tratamiento de diabetes tipo 2. | |
UA105000C2 (uk) | ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ СТЕАРОЇЛ-СоА-ДЕСАТУРАЗИ | |
MY169330A (en) | Method for inhibition of deubiquitinating activity |